Medical Pharmacology: Immunopharmacology (Immunosuppressants/Immunomodulators) Practice Questions

Medical Pharmacology: Immunopharmacology (Immunosuppressants/Immunomodulators) Practice Questions

"Yednock T Bench to Bedside: Multiple Sclerosis and Tysabri, Part 1"

Attribution:
- Yednock T Bench to Bedside: Multiple Sclerosis and Tysabri, Part 1 (2008)
  - Discovery and Development of Tysabri^® (Natalizumab) for the Treatment of Multiple Sclerosis [Part 1: Immune Cell Migration to the CNS]
  - https://www.ibiology.org/human-disease/tysabri/#part-1
- https://www.youtube.com/watch?v=iLGBwzXZqNc
  - Science Communication Lab https://www.youtube.com/@scicommlab

Click on the correct answer.

Natalizumab (Tysabri): using the treatment of which one(s) of the following:
1. Crohn's disease
2. Multiple sclerosis
3. Both
4. Neither
Natalizumab (Tysabri):
1. Humanized monoclonal antibody
2. Targets cell adhesion molecule α4-integrin
3. Both
4. Neither
The natalizumab target (α4-subunit of α4β1 and α4β7) integrin is found on leukocyte cell surfaces (except neutrophils).
1. True
2. False
Natalizumab:
1. Prevents α4-mediated binding leukocytes to the receptor
2. Appropriate for multiple sclerosis and Crohn's disease patients who have not been successfully treated with conventional therapeutic.
3. Both
4. Neither
Natalizumab (Tysabri):
1. Administration natalizumab limits risk of progressive multifocal leucoencephalopathy.
2. Should be routinely combined with anti-TNF-α drugs.
3. Both
4. Neither
Natalizumab:
1. Reduces progression rate of symptoms associated with multiple sclerosis flareups.
2. Reduces rate of relapse in patients with relapse-remitting MS
3. Both
4. Neither
Natalizumab (Tysabri) administration limits binding of α4-mediated leukocyte adhesion to:
1. Vascular cell adhesion molecule-1 (VCAM-1)
2. Mucosal vascular addressin cell adhesion molecule1
3. Both
4. Neither
Natalizumab administration:
1. Reduces inflammation by interfering with integrin receptor binding during an MS inflammatory flare
2. Prevents leukocytes from crossing blood vessels and inducing a pro-inflammatory reaction
3. Both
4. Neither
Natalizumab clinical use/uses:
1. Treatment of single, first occurrence of MS symptoms
2. Treatment of relapsing-remitting disease
3. Both
4. Neither
Natalizumab (Tysabri) is considered a monotherapy.
1. True
2. False

Previous Immunopharmacology Practice Question Set

Next Immunopharmacology Practice Question Set

"Yednock T Bench to Bedside: Multiple Sclerosis and Tysabri, Part 2"

Attribution:

Yednock T Bench to Bedside: Multiple Sclerosis and Tysabri, Part 2 (2008)

Discovery and Development of Tysabri^® (Natalizumab) for the Treatment of Multiple Sclerosis [Part 2: Response to the Emergence of PML (Progressive Multifocal Leukoencephalopathy)

https://www.ibiology.org/human-disease/tysabri/#part-2

https://www.youtube.com/watch?v=hQfoSj2fcxk

Science Communication Lab https://www.youtube.com/@scicommlab

Source Material:

Rothlin C Gutkind J Chapter 39 Immunosuppressants, Immunomodulation and Tolerance In Goodman & Gilman's The Pharmacological Basis of Therapeutics (Brunton LL Knollman BC eds) McGraw Hill LLC (2023).

Lake D & Briggs A Ch 55 Immunopharmacology in Katzung's Basic & Clinical Pharmacology (Vanderah TW, ed) 16e McGraw Hill 2023.

Babaesfahani A Khanna Patel P Kuns AB Natalizumab StatPearls https://www.ncbi.nlm.nih.gov/books/NBK534201/

Natalizumab: https://en.wikipedia.org/wiki/Natalizumab

Chrouos G Ch 39 Adrenocorticosteroids & Adrenocortical Antagonists in Katzung's Basic & Clinical Pharmacology (Vanderah TW, ed) 16e McGraw Hill 2023

Brezinski E Klickstein L Armstrong A Ch 46 Pharmacology of Immunosuppression in Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. (Golan DE Armstrong EJ Armstrong AW, eds) 4e 2017

Ritter JM Flower R Henderson G Loke YK MacEwan D Robinson E Fullerton J Ch 25 Anti-inflammatory and Immunosuppressant Drugs Rang & Dale's Pharmacology 10e Elsevier 2024.

Burchum J Rosenthal L Lehne's Pharmacology for Nursing Care Ch 72 Immunosuppressants Elsevier 2022.

Burchum J Rosenthal L Lehne's Pharmacology for Nursing Care Ch 75 Glucocorticoids in Nonendrocrine Disorders Elsevier 2022.

Burchum J Rosenthal L Lehne's Pharmacology for Nursing Care Ch 76 Drug Therapy for Rheumatoid Arthritis Elsevier 2022.

Bass A Rogatsky Ch 32 Immunomodulatory Drugs in Goldman-Cecil Medicine (Goldman L Schafer, eds) Elsevier 26e 2020

Leiva M Takemoto Ch 238 Immunosuppressants in Lippincott Illustrated Reviews: Pharmacology 8e ((Walen et al, eds) Wolters Kluwer 2023.

Hall J Hall M Ch 78 Adrenocortical Hormones Guyton and Hall Textbook of Medical Physiology 14e Elsevier 2021.

Waller DG Sampson A Hitchings Ch 38 The Immune Response and Immunosuppressant Drugs Medical Pharmacology & Therapeutics 6e Elsevier 2022

Waller DG Sampson A Hitchings Ch 30 Rheumotoid Arthritis, Other Inflammatory Arthrides and Osteoarthritis Medical Pharmacology & Therapeutics 6e Elsevier 2022